Zinc for COVID-19: real-time analysis of all 18 studies

Search:

Restrict: All Early Late Levels


6/15	In Vitro	Panchariya et al., bioRxiv, doi:10.1101/2021.06.15.448551 (Preprint) (In Vitro)	in vitro	Zinc2+ ion inhibits SARS-CoV-2 main protease and viral replication in vitro
	Details In Silico and In Vitro study showing that ionic zinc inhibits SARS-CoV-2 main protease (Mpro) and inhibits viral replication. Zinc acetate inhibited viral replication in Vero E6 cells, while zinc glycinate and zinc gluconate did not at n..
6/15	Details Source PDF In Vitro In Vitro
	Panchariya et al., bioRxiv, doi:10.1101/2021.06.15.448551 (Preprint) (In Vitro)
	Zinc2+ ion inhibits SARS-CoV-2 main protease and viral replication in vitro
	In Silico and In Vitro study showing that ionic zinc inhibits SARS-CoV-2 main protease (Mpro) and inhibits viral replication. Zinc acetate inhibited viral replication in Vero E6 cells, while zinc glycinate and zinc gluconate did not at non-toxic concentrations. The combination of zinc acetate with zinc ionophore quercetin signficantly improved inhibition at low concentrations. Panchariya et al., 6/15/2021, preprint, 14 authors.
	Share Tweet Submit Corrections or Comments
6/7	Late	Al Sulaiman et al., Research Square, doi:10.21203/rs.3.rs-572942/v1 (Preprint)	death, ↓35.0%, p=0.05	Evaluation of Zinc Sulfate as an Adjunctive Therapy in COVID-19 Critically Ill Patients: a Two Center Propensity-score Matched Study
	Details Retrospective 266 ICU patients showing lower mortality with zinc treatment (very close to statistical significance), and higher odds of acute kidney injury.
6/7	Details Source PDF Late treatment study Late treatment study
	Al Sulaiman et al., Research Square, doi:10.21203/rs.3.rs-572942/v1 (Preprint)
	Evaluation of Zinc Sulfate as an Adjunctive Therapy in COVID-19 Critically Ill Patients: a Two Center Propensity-score Matched Study
	Retrospective 266 ICU patients showing lower mortality with zinc treatment (very close to statistical significance), and higher odds of acute kidney injury. risk of death, 35.0% lower, RR 0.65, p = 0.05, treatment 35 of 130 (26.9%), control 45 of 129 (34.9%), adjusted, 30 day, PSM, multivariable Cox proportional hazards. risk of mechanical ventilation, 23.0% lower, RR 0.77, p = 0.52, treatment 20 of 57 (35.1%), control 23 of 54 (42.6%), adjusted, among non-mechanically ventilated patients within 24 hours of ICU admission. Al Sulaiman et al., 6/7/2021, retrospective, Saudi Arabia, Middle East, preprint, 10 authors.
	Share Tweet Submit Corrections or Comments
4/15	Levels	Skalny et al., Metabolites, doi:10.3390/metabo11040244 (Peer Reviewed)		Serum Zinc, Copper, and Other Biometals Are Associated with COVID-19 Severity Markers
	Details Analysis of serum metal levels in 150 COVID-19 patients and 44 controls, finding that COVID-19 severity was associated with lower serum Ca, Fe, Se, Zn levels when compared to controls.
4/15	Details Source PDF Levels Analysis of outcomes based on serum levels
	Skalny et al., Metabolites, doi:10.3390/metabo11040244 (Peer Reviewed)
	Serum Zinc, Copper, and Other Biometals Are Associated with COVID-19 Severity Markers
	Analysis of serum metal levels in 150 COVID-19 patients and 44 controls, finding that COVID-19 severity was associated with lower serum Ca, Fe, Se, Zn levels when compared to controls. Skalny et al., 4/15/2021, peer-reviewed, 14 authors.
	Share Tweet Submit Corrections or Comments
4/14	PEP	Seet et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.04.035 (Peer Reviewed)	severe case, ↓49.7%, p=0.03	Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial
	Details Prophylaxis RCT in Singapore with 3,037 low risk patients, showing lower serious cases, lower symptomatic cases, and lower confirmed cases of COVID-19 with all treatments (ivermectin, HCQ, PVP-I, and Zinc + vitamin C) compared to vitamin ..
4/14	Details Source PDF Post Exposure Prophylaxis study Post Exposure Prophylaxis study
	Seet et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.04.035 (Peer Reviewed)
	Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial
	Prophylaxis RCT in Singapore with 3,037 low risk patients, showing lower serious cases, lower symptomatic cases, and lower confirmed cases of COVID-19 with all treatments (ivermectin, HCQ, PVP-I, and Zinc + vitamin C) compared to vitamin C. Meta-analysis of vitamin C in 6 previous trials shows a benefit of 16%, so the actual benefit of ivermectin, HCQ, and PVP-I may be higher. Cluster RCT with 40 clusters. There were no hospitalizations and no deaths. NCT04446104. risk of COVID-19 severe case, 49.7% lower, RR 0.50, p = 0.03, treatment 33 of 634 (5.2%), control 64 of 619 (10.3%). risk of COVID-19 case, 26.9% lower, RR 0.73, p = 0.03, treatment 300 of 634 (47.3%), control 433 of 619 (70.0%), adjusted, OR converted to RR, model 6. Seet et al., 4/14/2021, Cluster Randomized Controlled Trial, Singapore, Asia, peer-reviewed, 15 authors, this trial compares with another treatment - results may be better when compared to placebo.
	Share Tweet Submit Corrections or Comments
2/13	Levels	Dubourg et al., Journal of Microbiology, Immunology and Infection, doi:10.1016/j.jmii.2021.01.012 (Peer Reviewed)		Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with Zinc COVID-19 patients?
	Details Retrospective 275 patients showing zinc levels significantly lower in patients with poor outcomes, 840 vs. 970 µg/L, p< 0.0001.
2/13	Details Source PDF Levels Analysis of outcomes based on serum levels
	Dubourg et al., Journal of Microbiology, Immunology and Infection, doi:10.1016/j.jmii.2021.01.012 (Peer Reviewed)
	Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with Zinc COVID-19 patients?
	Retrospective 275 patients showing zinc levels significantly lower in patients with poor outcomes, 840 vs. 970 µg/L, p< 0.0001. Dubourg et al., 2/13/2021, peer-reviewed, 8 authors.
	Share Tweet Submit Corrections or Comments
2/12	Early	Thomas et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.0369 (Peer Reviewed)	recov. time, ↓11.9%, p=0.38	Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial
	Details Small 214 low-risk outpatient RCT showing non-statistically significant faster recovery with zinc and with vitamin C. The zinc dosage appears low, 50mg zinc glcuonate (7mg elemental zinc). Study performed in the USA where zinc deficiency ..
2/12	Details Source PDF Early treatment study Early treatment study
	Thomas et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.0369 (Peer Reviewed)
	Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial
	Small 214 low-risk outpatient RCT showing non-statistically significant faster recovery with zinc and with vitamin C. The zinc dosage appears low, 50mg zinc glcuonate (7mg elemental zinc). Study performed in the USA where zinc deficiency is relatively uncommon. NCT04342728. The dose of zinc is a tenth of that shown to reduce duration of colds in other studies [1]. [1] patrickholford.com/blog/vitamin-c-speeds-up-covid-recovery recovery time, 11.9% lower, relative time 0.88, p = 0.38, treatment 58, control 50, mean time to a 50% reduction in symptoms, p value approximated with combined p value in study. Thomas et al., 2/12/2021, Randomized Controlled Trial, USA, North America, peer-reviewed, 11 authors.
	Share Tweet Submit Corrections or Comments
1/4	Review	Joachimiak et al., PLOS Neglected Tropical Diseases, doi:10.1371/journal.pntd.0008895 (Review) (Peer Reviewed)	review	Zinc against COVID-19? Symptom surveillance and deficiency risk groups
	Details Literature review concluding that zinc should be included as part of preventative supplementation for COVID-19, in general for support of immune health, and should also be considered in the context of zinc deficiency acquired during a vir..
1/4	Details Source PDF Review Review
	Joachimiak et al., PLOS Neglected Tropical Diseases, doi:10.1371/journal.pntd.0008895 (Review) (Peer Reviewed)
	Zinc against COVID-19? Symptom surveillance and deficiency risk groups
	Literature review concluding that zinc should be included as part of preventative supplementation for COVID-19, in general for support of immune health, and should also be considered in the context of zinc deficiency acquired during a viral infection and host immune response. Joachimiak et al., 1/4/2021, peer-reviewed, 1 author.
	Share Tweet Submit Corrections or Comments
12/30	Review	McCullough et al., Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm.2020.04.264 (Review) (Peer Reviewed)	review	Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)
	Details Review urging early treatment of COVID-19 with sequential multidrug treatment that has been shown to be safe and effective. Proposed treatment includes zinc, vitamin D & C, quercetin, and depending on age, comorbidities, and symptoms may ..
12/30	Details Source PDF Review Review
	McCullough et al., Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm.2020.04.264 (Review) (Peer Reviewed)
	Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)
	Review urging early treatment of COVID-19 with sequential multidrug treatment that has been shown to be safe and effective. Proposed treatment includes zinc, vitamin D & C, quercetin, and depending on age, comorbidities, and symptoms may include >=2 of HCQ, ivermectin, favipiravir; AZM/DOXY; corticosteroids; colchicine; bamlanivimab; aspirin; LMWH; and supplemental oxygen. McCullough et al., 12/30/2020, peer-reviewed, 58 authors.
	Share Tweet Submit Corrections or Comments
11/29	Late	Abd-Elsalam et al., Biological Trace Element Research, doi:10.1007/s12011-020-02512-1 (Peer Reviewed)	death, ↓1.0%, p=0.99	Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial
	Details 191 patient RCT in Egypt comparing the addition of zinc to HCQ, not showing a significant difference. Clinical recovery at 28 days was 79.2% in the zinc group and 77.9% control, p = 0.969. Mechanical ventilation was used with 4 patients..
11/29	Details Source PDF Late treatment study Late treatment study
	Abd-Elsalam et al., Biological Trace Element Research, doi:10.1007/s12011-020-02512-1 (Peer Reviewed)
	Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial
	191 patient RCT in Egypt comparing the addition of zinc to HCQ, not showing a significant difference. Clinical recovery at 28 days was 79.2% in the zinc group and 77.9% control, p = 0.969. Mechanical ventilation was used with 4 patients in the zinc group and 6 control. There were 5 deaths in each group. No information on baseline zinc values was recorded. We note that Egypt has a low rate of zinc deficiency so supplementation is less likely to be helpful in Egypt [1, 2] [1] ncbi.nlm.nih.gov/pmc/articles/PMC3510072/ [2] ncbi.nlm.nih.gov/pmc/articles/PMC3510072/bin/pone.0050568.s003.xls risk of death, 1.0% lower, RR 0.99, p = 0.99, treatment 5 of 96 (5.2%), control 5 of 95 (5.3%). risk of mechanical ventilation, 34.0% lower, RR 0.66, p = 0.54, treatment 4 of 96 (4.2%), control 6 of 95 (6.3%). risk of no recovery, 5.8% lower, RR 0.94, p = 0.97, treatment 20 of 96 (20.8%), control 21 of 95 (22.1%). hospitalization time, 3.6% lower, relative time 0.96, p = 0.55, treatment 96, control 95. Abd-Elsalam et al., 11/29/2020, Randomized Controlled Trial, Egypt, Middle East, peer-reviewed, 10 authors.
	Share Tweet Submit Corrections or Comments
11/18	In Silico	Pormohammad et al., International Journal of Molecular Medicine, doi:10.3892/ijmm.2020.4790 (Peer Reviewed)		Zinc and SARS‑CoV‑2: A molecular modeling study of Zn interactions with RNA‑dependent RNA‑polymerase and 3C‑like proteinase enzymes
	Details In Silico analysis supporting the hypothesis that Zn would bind and regulate the enzymatic activities of 3CLpro and RdRp of SARS‑CoV-2 and therefore inhibit viral replication. Since Zn has established immune health benefits, is readily av..
11/18	Details Source PDF In Silico In Silico
	Pormohammad et al., International Journal of Molecular Medicine, doi:10.3892/ijmm.2020.4790 (Peer Reviewed)
	Zinc and SARS‑CoV‑2: A molecular modeling study of Zn interactions with RNA‑dependent RNA‑polymerase and 3C‑like proteinase enzymes
	In Silico analysis supporting the hypothesis that Zn would bind and regulate the enzymatic activities of 3CLpro and RdRp of SARS‑CoV-2 and therefore inhibit viral replication. Since Zn has established immune health benefits, is readily available, inexpensive and safe, the authors propose that Zn could help ameliorate COVID-19. Pormohammad et al., 11/18/2020, peer-reviewed, 3 authors.
	Share Tweet Submit Corrections or Comments
10/26	Late	Frontera et al., Research Square, doi:10.21203/rs.3.rs-94509/v1 (Preprint)	death, ↓37.0%, p=0.01	Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study
	Details Retrospective 3,473 hospitalized patients showing 37% lower mortality with HCQ+zinc. PSM aHR 0.63, p=0.015 regression aHR 0.76, p = 0.023
10/26	Details Source PDF Late treatment study Late treatment study
	Frontera et al., Research Square, doi:10.21203/rs.3.rs-94509/v1 (Preprint)
	Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study
	Retrospective 3,473 hospitalized patients showing 37% lower mortality with HCQ+zinc. PSM aHR 0.63, p=0.015 regression aHR 0.76, p = 0.023 risk of death, 37.0% lower, RR 0.63, p = 0.01, treatment 121 of 1006 (12.0%), control 424 of 2467 (17.2%), adjusted, PSM. risk of death, 24.0% lower, RR 0.76, p = 0.02, treatment 121 of 1006 (12.0%), control 424 of 2467 (17.2%), adjusted, regression. Frontera et al., 10/26/2020, retrospective, USA, North America, preprint, median age 64.0, 14 authors.
	Share Tweet Submit Corrections or Comments
10/26	Levels	Berrocal et al., Research Square, doi:10.21203/rs.3.rs-95524/v1 (Preprint)	death, ↓44.8%, p=0.23	Zinc and Vitamin A Deficiency Predisposes to the Need for Intubation and ICU Admission in Patients With COVID-19. An Observational Study
	Details Retrospective 120 hospitalized patients showing zinc deficiency associated with a higher ICU admission rate (61.8% vs.29%; p = 0.002) and a higher rate of intubation (87.5% vs. 12.5%; p = 0.002).
10/26	Details Source PDF Levels Analysis of outcomes based on serum levels
	Berrocal et al., Research Square, doi:10.21203/rs.3.rs-95524/v1 (Preprint)
	Zinc and Vitamin A Deficiency Predisposes to the Need for Intubation and ICU Admission in Patients With COVID-19. An Observational Study
	Retrospective 120 hospitalized patients showing zinc deficiency associated with a higher ICU admission rate (61.8% vs.29%; p = 0.002) and a higher rate of intubation (87.5% vs. 12.5%; p = 0.002). risk of death, 44.8% lower, RR 0.55, p = 0.23, treatment 5 of 31 (16.1%), control 26 of 89 (29.2%). risk of ICU admission, 53.0% lower, RR 0.47, p = 0.003, treatment 9 of 31 (29.0%), control 55 of 89 (61.8%). Berrocal et al., 10/26/2020, retrospective, preprint, 7 authors.
	Share Tweet Submit Corrections or Comments
10/26	Early	Derwand et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106214 (preprint 7/3) (Peer Reviewed)	death, ↓79.4%, p=0.12	COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study
	Details 79% lower mortality and 82% lower hospitalization with early HCQ+AZ+Z. Retrospective 518 patients (141 treated, 377 control).
10/26	Details Source PDF Early treatment study Early treatment study
	Derwand et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106214 (preprint 7/3) (Peer Reviewed)
	COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study
	79% lower mortality and 82% lower hospitalization with early HCQ+AZ+Z. Retrospective 518 patients (141 treated, 377 control). risk of death, 79.4% lower, RR 0.21, p = 0.12, treatment 1 of 141 (0.7%), control 13 of 377 (3.4%), OR converted to RR. risk of hospitalization, 81.6% lower, RR 0.18, p < 0.001, treatment 4 of 141 (2.8%), control 58 of 377 (15.4%), OR converted to RR. Derwand et al., 10/26/2020, retrospective, USA, North America, peer-reviewed, 3 authors.
	Share Tweet Submit Corrections or Comments
10/20	PrEP	Heller et al., Redox Biology, doi:10.1016/j.redox.2020.101764 (Peer Reviewed)		Prediction of Survival Odds in COVID-19 by Zinc, Age and Selenoprotein P as Composite Biomarker
	Details Analysis of 35 COVID-19 patients showing a significant correlation for serum zinc levels between COVID-19 patients and controls, and between COVID-19 survivors and non-survivors.
10/20	Details Source PDF Pre-Exposure Prophylaxis study Pre-Exposure Prophylaxis study
	Heller et al., Redox Biology, doi:10.1016/j.redox.2020.101764 (Peer Reviewed)
	Prediction of Survival Odds in COVID-19 by Zinc, Age and Selenoprotein P as Composite Biomarker
	Analysis of 35 COVID-19 patients showing a significant correlation for serum zinc levels between COVID-19 patients and controls, and between COVID-19 survivors and non-survivors. Heller et al., 10/20/2020, peer-reviewed, 14 authors.
	Share Tweet Submit Corrections or Comments
10/11	Late	Vogel-González et al., medRxiv, doi:10.1101/2020.10.07.20208645 (Preprint)		Low zinc levels at clinical admission associates with poor outcomes in COVID-19
	Details Shows a correlation between serum zinc levels and COVID-19 outcome. Almost all patients received HCQ.
10/11	Details Source PDF Late treatment study Late treatment study
	Vogel-González et al., medRxiv, doi:10.1101/2020.10.07.20208645 (Preprint)
	Low zinc levels at clinical admission associates with poor outcomes in COVID-19
	Shows a correlation between serum zinc levels and COVID-19 outcome. Almost all patients received HCQ. Vogel-González et al., 10/11/2020, Spain, Europe, preprint, 16 authors.
	Share Tweet Submit Corrections or Comments
9/10	Levels	Jothimani (Peer Reviewed)	death, ↓89.7%, p=0.06	COVID-19: Poor outcomes in patients with zinc deficiency
	Details Prospective study of zinc levels in 47 hospitalized COVID-19 patients and 45 healthy controls. COVID-19 patients had significantly lower zinc levels (74.5 vs. 105.8 median μg/dl, p < 0.001). 57.4% of COVID-19 patients were zinc deficient,..
9/10	Details Source PDF Levels Analysis of outcomes based on serum levels
	Jothimani (Peer Reviewed)
	COVID-19: Poor outcomes in patients with zinc deficiency
	Prospective study of zinc levels in 47 hospitalized COVID-19 patients and 45 healthy controls. COVID-19 patients had significantly lower zinc levels (74.5 vs. 105.8 median μg/dl, p < 0.001). 57.4% of COVID-19 patients were zinc deficient, and they had higher rates of complications, ARDS, prolonged hospital stay, and increased mortality. risk of death, 89.7% lower, RR 0.10, p = 0.06, treatment 0 of 20 (0.0%), control 5 of 27 (18.5%), continuity correction due to zero event. risk of ICU admission, 92.4% lower, RR 0.08, p = 0.02, treatment 0 of 20 (0.0%), control 7 of 27 (25.9%), continuity correction due to zero event. Jothimani et al., 9/10/2020, prospective, India, South Asia, peer-reviewed, 11 authors.
	Share Tweet Submit Corrections or Comments
9/7	Levels	Yasui et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.09.008 (Peer Reviewed)	ventilation, ↓92.5%, p=0.001	Analysis of the predictive factors for a critical illness of COVID-19 during treatment － relationship between serum zinc level and critical illness of COVID-19
	Details Retrospective 62 hospitalized patients, 29 with serum zinc data, showing significantly lower serum zinc levels for severe COVID-19 cases (intubation) compared with mild and moderate cases, p = 0.005. Authors recommend zinc supplementation.
9/7	Details Source PDF Levels Analysis of outcomes based on serum levels
	Yasui et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.09.008 (Peer Reviewed)
	Analysis of the predictive factors for a critical illness of COVID-19 during treatment － relationship between serum zinc level and critical illness of COVID-19
	Retrospective 62 hospitalized patients, 29 with serum zinc data, showing significantly lower serum zinc levels for severe COVID-19 cases (intubation) compared with mild and moderate cases, p = 0.005. Authors recommend zinc supplementation. risk of mechanical ventilation, 92.5% lower, RR 0.08, p = 0.001, treatment 1 of 20 (5.0%), control 6 of 9 (66.7%), zinc >= 70μg/dL. Yasui et al., 9/7/2020, retrospective, Japan, Asia, peer-reviewed, 10 authors.
	Share Tweet Submit Corrections or Comments
7/22	Late	Yao et al., Chest, doi:10.1016/j.chest.2020.06.082 (Peer Reviewed)	death, ↓34.0%, p=0.09	The Minimal Effect of Zinc on the Survival of Hospitalized Patients With COVID-19
	Details Retrospective 242 hospitalized patients in the USA showing adjusted hazard ratio for zinc treatment, aHR 0.66 [0.41-1.07]. [1] notes that the study would be more informative if baseline serum zinc levels were known.
7/22	Details Source PDF Late treatment study Late treatment study
	Yao et al., Chest, doi:10.1016/j.chest.2020.06.082 (Peer Reviewed)
	The Minimal Effect of Zinc on the Survival of Hospitalized Patients With COVID-19
	Retrospective 242 hospitalized patients in the USA showing adjusted hazard ratio for zinc treatment, aHR 0.66 [0.41-1.07]. [1] notes that the study would be more informative if baseline serum zinc levels were known. [1] ncbi.nlm.nih.gov/pmc/articles/PMC7836617/ risk of death, 34.0% lower, RR 0.66, p = 0.09, treatment 73 of 196 (37.2%), control 21 of 46 (45.7%), adjusted. Yao et al., 7/22/2020, retrospective, USA, North America, peer-reviewed, 9 authors.
	Share Tweet Submit Corrections or Comments
6/6	Late	Finzi et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.06.006 (Peer Reviewed)		Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients
	Details Case report on 4 patients treated with high dose zinc. All patients experienced significant improvement after one day.
6/6	Details Source PDF Late treatment study Late treatment study
	Finzi et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.06.006 (Peer Reviewed)
	Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients
	Case report on 4 patients treated with high dose zinc. All patients experienced significant improvement after one day. Finzi et al., 6/6/2020, peer-reviewed, 1 author.
	Share Tweet Submit Corrections or Comments
5/8	Late	Carlucci et al., J. Med. Microbiol., Sep 15, 2020, doi: 10.1099/jmm.0.001250 (preprint 5/8) (Peer Reviewed)	death/HPC, ↓37.8%, p=0.002	Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients
	Details Retrospective 932 patients. Addition of Zinc to HCQ+AZ reduces mortality / transfer to hospice, ICU admission, and the need for ventilation. Reduction in mortality or transfer to hospice adjusted odds ratio OR 0.56, p = 0.002; increase i..
5/8	Details Source PDF Late treatment study Late treatment study
	Carlucci et al., J. Med. Microbiol., Sep 15, 2020, doi: 10.1099/jmm.0.001250 (preprint 5/8) (Peer Reviewed)
	Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients
	Retrospective 932 patients. Addition of Zinc to HCQ+AZ reduces mortality / transfer to hospice, ICU admission, and the need for ventilation. Reduction in mortality or transfer to hospice adjusted odds ratio OR 0.56, p = 0.002; increase in being discharged home, adjusted OR 1.53, p = 0.008. risk of combined death/hospice, 37.8% lower, RR 0.62, p = 0.002, treatment 411, control 521, OR converted to RR. Carlucci et al., 5/8/2020, retrospective, peer-reviewed, 6 authors.
	Share Tweet Submit Corrections or Comments
2010	In Vitro	te Velthuis et al., PLOS Pathogens 2010, 6:11, doi:10.1371/journal.ppat.1001176 (Peer Reviewed) (In Vitro)	in vitro	Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture
	Details Shows that the combination of Zn2+ and a zinc ionophore (pyrithione) at low concentrations inhibits the replication of SARS-CoV and equine arteritis virus (EAV) in cell culture. Recommends further study of the use of zinc-ionophores as an..
2010	Details Source PDF In Vitro In Vitro
	te Velthuis et al., PLOS Pathogens 2010, 6:11, doi:10.1371/journal.ppat.1001176 (Peer Reviewed) (In Vitro)
	Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture
	Shows that the combination of Zn2+ and a zinc ionophore (pyrithione) at low concentrations inhibits the replication of SARS-CoV and equine arteritis virus (EAV) in cell culture. Recommends further study of the use of zinc-ionophores as antiviral compounds. te Velthuis et al., 1/1/2010, peer-reviewed, 6 authors.
	Share Tweet Submit Corrections or Comments

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit